Table 1 Current drugs in development that target the PI3K or related pathways Figure 1: Schematic of signalling through the phosphatidylinositol-3-kinase (PI3K)/AKT pathway. Class 1B PI3Ks consist ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

The approval is for unresectable or recurrent phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, AKT serine/threonine kinase 1 or phosphatase and tensin homolog-altered ...

We have shown that inhibitors of PI3K, AKT, and mTOR all relieve feedback ... Our recent work has shown that Hsp90 is critical for oncogenic RAF kinase-driven ERK activation. The combination of Hsp90 ...